The impact of the Oncotype DX recurrence score pathology-clinical (RSPC) on the predicted recurrence risk for node negative breast cancer patients: A cancer center experience

Authors :: Barbara L. Smith
Barbara A. Wexelman
Steven J. Isakoff
Alexander Gallagher
Source :: Journal of Clinical Oncology. 32:570-570
Publication Year :: 2014
Publisher :: American Society of Clinical Oncology (ASCO), 2014.
Abstract: 570 Background: The OncotypeDX 21-gene assay Recurrence Score (RS) is widely used to risk-stratify ER+, node negative breast cancer to determine the 10 year risk of distant recurrence (RR) and the ...

Subjects :: Cancer Research
Pathology
medicine.medical_specialty
medicine.diagnostic_test
business.industry
Recurrence score
Distant recurrence
Cancer
medicine.disease
Node negative
Recurrence risk
Breast cancer
Oncology
Medicine
business
Oncotype DX

Full Text Access

Tools